CCR6

C-C chemokine receptor type 6 · P51684 · CCR6 on Sugi Atlas →

57,747 patent compounds predicted against CCR6, 37,604 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL381811)	0.51	12/20
SCHEMBL246834	0.92	6/20
SCHEMBL255377	0.43	5/20
SCHEMBL25445	1.00	4/20
SCHEMBL331584	0.40	4/20
SCHEMBL146609	0.40	3/20
Sphingosine (SCHEMBL19398)	1.00	2/20
Sphingosine (SCHEMBL19399)	1.00	2/20
Sphingosine (SCHEMBL195874)	0.97	2/20
Sphingosine (SCHEMBL195875)	0.97	2/20
SCHEMBL144792	0.91	2/20
Sphingosine (SCHEMBL19137)	0.85	2/20
Sphingosine (SCHEMBL320150)	0.85	2/20
SCHEMBL248295	0.78	2/20
SCHEMBL248399	0.69	2/20
SCHEMBL248274	0.69	2/20
SCHEMBL312332	0.65	2/20
SCHEMBL331752	0.62	2/20
SCHEMBL247709	0.61	2/20
Dimethylspingosine (SCHEMBL121926)	0.61	2/20

Clinical trials — most relevant to CCR6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation	PHASE3	SUSPENDED
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia	PHASE3	SUSPENDED
Polyvalent Immunoglobulin in COVID-19 Related ARds	PHASE3	COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver	PHASE2	COMPLETED
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients	PHASE1/PHASE2	COMPLETED
Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis	PHASE2	COMPLETED
Quantitating the Impact of Plerixafor	PHASE1/PHASE2	UNKNOWN
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment	PHASE2	UNKNOWN
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)	PHASE1	RECRUITING
Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation	PHASE1	COMPLETED
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation	PHASE1	RECRUITING
Evaluation of CCR6 Gene Expression and Circulating CCL20 Levels as Potential Biomarkers in Rheumatoid Arthritis	nan	NOT_YET_RECRUITING
IL-11 in the Development of Multiple Sclerosis	nan	UNKNOWN
Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure	nan	UNKNOWN
Inflammatory Biomarkers in Seizure	nan	UNKNOWN
The Influence of Extracorporeal Photopheresis on Skin Sclerosis	nan	COMPLETED
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response	nan	ACTIVE_NOT_RECRUITING
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma	nan	UNKNOWN
Circular RNA and Chemerin in Breast Cancer Patient	nan	UNKNOWN
Significance of MAIT Cells in Inflammatory Bowel Disease	nan	UNKNOWN
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma	nan	UNKNOWN
Measuring the Healthy Pediatric Inflammatory Response to Vaccination.	nan	ENROLLING_BY_INVITATION
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia	nan	RECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver	nan	COMPLETED
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy	nan	COMPLETED
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis	nan	UNKNOWN
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity	nan	NOT_YET_RECRUITING
Value of Various Chemokines in the Detection and Follow up of RCC	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCR6 binder may also engage these)

Protein	Name	Similarity
O54689	—	0.999	O54689 →
P56482	—	0.998	P56482 →
Q95ND1	—	0.997	Q95ND1 →
CCR7	C-C chemokine receptor type 7	0.997	landscape →
P56491	—	0.997	P56491 →
O19024	—	0.997	O19024 →
P61815	—	0.996	P61815 →
CCR1	C-C chemokine receptor type 1	0.996	landscape →
Q5MD62	—	0.996	Q5MD62 →
Q2KTE1	—	0.996	Q2KTE1 →
P51676	—	0.996	P51676 →
P47774	—	0.995	P47774 →
P56439	—	0.995	P56439 →
O97962	—	0.995	O97962 →
P61072	—	0.995	P61072 →
O97880	—	0.995	O97880 →
P51683	—	0.995	P51683 →
Q7YS92	—	0.995	Q7YS92 →
Q9NPB9	—	0.995	Q9NPB9 →
Q9TV48	—	0.995	Q9TV48 →
Q95NE8	—	0.995	Q95NE8 →
A6QNL7	—	0.995	A6QNL7 →
Q28474	—	0.995	Q28474 →
P61755	—	0.995	P61755 →
P61757	—	0.994	P61757 →
O97879	—	0.994	O97879 →
Q2YEG0	—	0.994	Q2YEG0 →
O97571	—	0.994	O97571 →
O97883	—	0.994	O97883 →
Q9BDS6	—	0.994	Q9BDS6 →